Literature DB >> 34250399

Debio1347, an Oral FGFR Inhibitor: Results From a Single-Center Study in Pediatric Patients With Recurrent or Refractory FGFR-Altered Gliomas.

Sameer Farouk Sait1,2, Stephen W Gilheeney1,2, Tejus A Bale3, Sofia Haque4, Marc J Dinkin5, Stephanie Vitolano1, Marc K Rosenblum3, Katarzyna Ibanez6, Daniel E Prince7, Krisoula H Spatz8, Ira J Dunkel1,2, Matthias A Karajannis1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34250399      PMCID： PMC8232545          DOI： 10.1200/PO.20.00444

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  19 in total

1.  Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation.

Authors:  David Castel; Thomas Kergrohen; Arnault Tauziède-Espariat; Alan Mackay; Samia Ghermaoui; Emmanuèle Lechapt; Stefan M Pfister; Christof M Kramm; Nathalie Boddaert; Thomas Blauwblomme; Stéphanie Puget; Kévin Beccaria; Chris Jones; David T W Jones; Pascale Varlet; Jacques Grill; Marie-Anne Debily
Journal:  Acta Neuropathol       Date:  2020-03-19       Impact factor: 17.088

2.  Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.

Authors:  R Bahleda; F Meric-Bernstam; L Goyal; B Tran; Y He; I Yamamiya; K A Benhadji; I Matos; H-T Arkenau
Journal:  Ann Oncol       Date:  2020-07-02       Impact factor: 32.976

3.  Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.

Authors:  Rastislav Bahleda; Antoine Italiano; Cinta Hierro; Alain Mita; Andres Cervantes; Nancy Chan; Mark Awad; Emiliano Calvo; Victor Moreno; Ramaswamy Govindan; Alexander Spira; Martha Gonzalez; Bob Zhong; Ademi Santiago-Walker; Italo Poggesi; Trilok Parekh; Hong Xie; Jeffrey Infante; Josep Tabernero
Journal:  Clin Cancer Res       Date:  2019-05-14       Impact factor: 12.531

4.  Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1.

Authors:  Philipp Sievers; Romain Appay; Daniel Schrimpf; Damian Stichel; David E Reuss; Annika K Wefers; Annekathrin Reinhardt; Roland Coras; Viktoria C Ruf; Simone Schmid; Karin de Stricker; Henning B Boldt; Bjarne Winther Kristensen; Jeanette Krogh Petersen; Benedicte P Ulhøi; Maria Gardberg; Eleonora Aronica; Martin Hasselblatt; Wolfgang Brück; Franck Bielle; Karima Mokhtari; Benoît Lhermitte; Wolfgang Wick; Christel Herold-Mende; Daniel Hänggi; Sebastian Brandner; Felice Giangaspero; David Capper; Elisabeth Rushing; Pieter Wesseling; Stefan M Pfister; Dominique Figarella-Branger; Andreas von Deimling; Felix Sahm; David T W Jones
Journal:  Acta Neuropathol       Date:  2019-06-27       Impact factor: 17.088

Review 5.  Advances and challenges in targeting FGFR signalling in cancer.

Authors:  Irina S Babina; Nicholas C Turner
Journal:  Nat Rev Cancer       Date:  2017-03-17       Impact factor: 60.716

6.  A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.

Authors:  Martin H Voss; Cinta Hierro; Rebecca S Heist; James M Cleary; Funda Meric-Bernstam; Josep Tabernero; Filip Janku; Leena Gandhi; A John Iafrate; Darrell R Borger; Nobuya Ishii; Youyou Hu; Yulia Kirpicheva; Valerie Nicolas-Metral; Anna Pokorska-Bocci; Anne Vaslin Chessex; Claudio Zanna; Keith T Flaherty; Jose Baselga
Journal:  Clin Cancer Res       Date:  2019-02-11       Impact factor: 13.801

Review 7.  Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.

Authors:  Cinta Hierro; Jordi Rodon; Josep Tabernero
Journal:  Semin Oncol       Date:  2015-09-24       Impact factor: 4.929

8.  Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.

Authors:  Josep Tabernero; Rastislav Bahleda; Rodrigo Dienstmann; Jeffrey R Infante; Alain Mita; Antoine Italiano; Emiliano Calvo; Victor Moreno; Barbara Adamo; Anas Gazzah; Bob Zhong; Suso J Platero; Johan W Smit; Kim Stuyckens; Moitreyee Chatterjee-Kishore; Jordi Rodon; Vijay Peddareddigari; Feng R Luo; Jean-Charles Soria
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

9.  The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.

Authors:  Yoshito Nakanishi; Nukinori Akiyama; Toshiyuki Tsukaguchi; Toshihiko Fujii; Kiyoaki Sakata; Hitoshi Sase; Takehito Isobe; Kenji Morikami; Hidetoshi Shindoh; Toshiyuki Mio; Hirosato Ebiike; Naoki Taka; Yuko Aoki; Nobuya Ishii
Journal:  Mol Cancer Ther       Date:  2014-08-28       Impact factor: 6.261

Review 10.  Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.

Authors:  R Dienstmann; J Rodon; A Prat; J Perez-Garcia; B Adamo; E Felip; J Cortes; A J Iafrate; P Nuciforo; J Tabernero
Journal:  Ann Oncol       Date:  2013-11-20       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.